03.19.14
Autonomic Technologies Inc. has a new chief medical officer.
The Redwood City, Calif., company recently appointed Shashidhar Kori, M.D., as chief medical officer. Kori has more than 30 years experience in neurosciences. Most recently, he was vice president of Clinical Development and Medical Affairs at Allergan and MAP Pharmaceuticals. Previously he was senior director of Clinical Development and Senior Medical Advisor on the pain/migraine team at GlaxoSmithKline. In these roles, Kori led the design and execution of numerous clinical studies to support product development and commercialization, built and oversaw an active publication strategy, created a new medical affairs department, served as liaison to the external scientific and medical community, and was involved in both new product development and discussions with global regulatory authorities.
In his new role, Kori is responsible for clinical research, clinical outcomes, and regulatory submissions. He will oversee development and execution of all clinical research, including clinical trials of the ATI Neurostimulation System for cluster headache and migraine in the United States and in Europe. He also will lead interactions with regulatory authorities.
“Dr. Kori brings a wealth of experience to ATI from many years of work at leading pharmaceutical companies in the headache space and also as a physician,” ATI President/CEO Ben Pless said. "Shashi is widely recognized and well respected in the field of neurology and neuroscience, and headache in particular. We are pleased and fortunate to have such a capable and accomplished leader join ATI at this important point in our company’s growth."
Kori founded, built, and ran four large pain programs, including the Pain and Palliative Care Program at Duke University, where he was the founding director. He founded and managed large clinical and residency programs, and he held leadership, teaching, and administrative posts at Duke University, the University of South Florida College of Medicine, and Case Western Reserve University. Kori has held positions in the American Academy of Neurology, Southern Pain Society, American Society for Neuroimaging, and the South Eastern Academic Pain Consortium. He also has authored more than 90 publications, served on editorial boards of medical journals, and has given more than 150 U.S. and international invited lectures on pain and headache management.
Kori received his medical degree from Kasturba Medical College in Mangalore, India. He completed residencies in Internal Medicine at the VA Medical Center in Brooklyn, N.Y., and Neurology at St. Vincent’s Hospital and Medical Center in New York, N.Y. He served fellowships in Neuro-oncology, Neuroimmunology and Immunobiology, and Cancer Pain at Memorial Sloan-Kettering Cancer Center in Manhattan.
Autonomic Technologies develops severe headache treatment therapies. The company’s initial product, the ATI Neurostimulation System, is CE marked in Europe for the treatment of cluster headache and currently is being investigated in a multi-center, randomized study for the treatment of high frequency, high disability migraine. ATI is backed by blue chip investors Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic.
The Redwood City, Calif., company recently appointed Shashidhar Kori, M.D., as chief medical officer. Kori has more than 30 years experience in neurosciences. Most recently, he was vice president of Clinical Development and Medical Affairs at Allergan and MAP Pharmaceuticals. Previously he was senior director of Clinical Development and Senior Medical Advisor on the pain/migraine team at GlaxoSmithKline. In these roles, Kori led the design and execution of numerous clinical studies to support product development and commercialization, built and oversaw an active publication strategy, created a new medical affairs department, served as liaison to the external scientific and medical community, and was involved in both new product development and discussions with global regulatory authorities.
In his new role, Kori is responsible for clinical research, clinical outcomes, and regulatory submissions. He will oversee development and execution of all clinical research, including clinical trials of the ATI Neurostimulation System for cluster headache and migraine in the United States and in Europe. He also will lead interactions with regulatory authorities.
“Dr. Kori brings a wealth of experience to ATI from many years of work at leading pharmaceutical companies in the headache space and also as a physician,” ATI President/CEO Ben Pless said. "Shashi is widely recognized and well respected in the field of neurology and neuroscience, and headache in particular. We are pleased and fortunate to have such a capable and accomplished leader join ATI at this important point in our company’s growth."
Kori founded, built, and ran four large pain programs, including the Pain and Palliative Care Program at Duke University, where he was the founding director. He founded and managed large clinical and residency programs, and he held leadership, teaching, and administrative posts at Duke University, the University of South Florida College of Medicine, and Case Western Reserve University. Kori has held positions in the American Academy of Neurology, Southern Pain Society, American Society for Neuroimaging, and the South Eastern Academic Pain Consortium. He also has authored more than 90 publications, served on editorial boards of medical journals, and has given more than 150 U.S. and international invited lectures on pain and headache management.
Kori received his medical degree from Kasturba Medical College in Mangalore, India. He completed residencies in Internal Medicine at the VA Medical Center in Brooklyn, N.Y., and Neurology at St. Vincent’s Hospital and Medical Center in New York, N.Y. He served fellowships in Neuro-oncology, Neuroimmunology and Immunobiology, and Cancer Pain at Memorial Sloan-Kettering Cancer Center in Manhattan.
Autonomic Technologies develops severe headache treatment therapies. The company’s initial product, the ATI Neurostimulation System, is CE marked in Europe for the treatment of cluster headache and currently is being investigated in a multi-center, randomized study for the treatment of high frequency, high disability migraine. ATI is backed by blue chip investors Kleiner Perkins Caufield and Byers, InterWest Partners, Versant Ventures, Novartis Ventures, Aberdare Ventures, and the Cleveland Clinic.